SBJ logo

YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Johnson & Johnson to buy Swiss biopharma firm for $30B

Posted online
Johnson & Johnson set in motion plans to buy Swiss biopharmaceutical company Actelion Ltd. for $30 billion.

J&J officials say the deal that's expect to close in the second quarter would immediately bump up its earnings per share and revenue.

Actelion’s drugs Tracleer, Opsumit and Uptravi all treat life-threatening pulmonary arterial hypertension.

Read more from USA Today.


Comments

No comments on this story |
Please log in to add your comment
More from SBJ Daily Update

Republic School District opens activities center

Advanced search
Editors' Pick
Fall 2026 Architects & Engineers Project Report

This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.

Most Read

Longtime employee sues Ozarks Tech, alleges retaliation

Cavender’s opens hat shop in southeast Springfield

Eric Schmitt introduces Modern Skies Act

Caterpillar to acquire John Fabick Tractor Co.

Springfield airport to cut the ribbon on $35M in construction projects

Legacy Bank accused in lawsuit of failing to protect customers in data breach

Branson hires new communications director

SBJ.net Poll
Springfield's jobless rate ticked down from July to August, according to the latest federal data. Is your firm expanding its workforce?

*

View results

© 2026, Springfield Business Journal, Springfield, Missouri. All Rights Reserved.
Powered by Creative Circle Media Solutions
Update cookies preferences